Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Need a quote from a Motley Fool analyst? Over the past decade, Recursion Pharmaceuticals, Inc. has built something truly special: a differentiated platform pioneering the integration of large-scale ...

Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...

It’s more than just code. Scientists have found a way to "dial" the hidden personalities of AI, from conspiracy theorists to ...

A team of researchers has found a way to steer the output of large language models by manipulating specific concepts inside these models. The new ...

A team of researchers has found a way to steer the output of large language models by manipulating specific concepts inside these models. The new method could lead to more reliable, more efficient, ...

Nvidia sold its entire 7.71M share stake as ARK Invest bought 1.25M shares; RXRX swung 14% before closing 2% higher Wednesday.

NVIDIA’s most recent 13F filing showed no position in Recursion Pharmaceuticals, indicating a complete exit from its previous ...

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...

If you are trying to figure out whether Recursion Pharmaceuticals is attractively priced or a high risk speculation, a useful starting point is understanding what the current market price might be ...

A Samsung AI researcher in Montreal has created a tiny AI model that punches far above its weight, challenging the industry’s focus on massive scale. Released this week, the 7-million-parameter Tiny ...